Home > Boards > US Listed > Alternative Energy > Amyris, Inc. (AMRS)

The Struggle Continues, AMRS Shall State end of Dilution

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
finesand Member Profile
 
Followed By 29
Posts 2,841
Boards Moderated 0
Alias Born 03/17/17
160x600 placeholder
Amyris To Host Third Quarter 2020 Financial Results Conference Call On November 5 PR Newswire (US) - 10/23/2020 8:00:00 AM
Amyris and The Infectious Disease Research Institute Enter into Exclusive License for Novel RNA Vaccine Platform, Beginning w... PR Newswire (US) - 10/22/2020 8:00:00 AM
Amyris and Arzeda Enter into Development Collaboration Agreement PR Newswire (US) - 10/20/2020 9:30:00 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 10/2/2020 5:04:39 PM
Amyris Delivering Sustainable Alternative To Shark Squalene Adjuvant - Enabling Vaccines For All With No Sharks Killed PR Newswire (US) - 10/1/2020 8:30:00 AM
Amyris' Pipette Clean Baby Brand Selected By Alibaba For Accelerated Entry Into China For Singles' Day Sales PR Newswire (US) - 9/21/2020 8:30:00 AM
Amyris Continues Market Adoption Of Its Sweetener With Approval By Health Canada PR Newswire (US) - 9/15/2020 8:30:00 AM
Amyris to Provide Business Overview And Update On Current Affairs At H.C. Wainwright 22nd Annual Global Investment Conference... PR Newswire (US) - 9/14/2020 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/11/2020 9:11:59 AM
Amyris Responds To LAVVAN's Filing Of Lawsuit On September 10, 2020 PR Newswire (US) - 9/11/2020 5:00:00 AM
LAVVAN, Inc. Files $881 Million Federal Lawsuit Against Amyris, Inc. For Patent Infringement and Trade Secret Misappropriatio... PR Newswire (US) - 9/10/2020 3:41:00 PM
LAVVAN, Inc. Files $881 Million Federal Lawsuit Against Amyris, Inc. For Patent Infringement and Trade Secret Misappropriatio... PR Newswire (Canada) - 9/10/2020 3:41:00 PM
Amyris to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 PR Newswire (US) - 9/8/2020 8:30:00 AM
Amyris Scales First Fermentation-Based Cannabinoid PR Newswire (US) - 9/1/2020 8:30:00 AM
Amyris Scales First Fermentation-Based Cannabinoid PR Newswire (Canada) - 9/1/2020 8:30:00 AM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 8/28/2020 7:46:50 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 8/28/2020 7:46:35 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 8/28/2020 7:46:05 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 8/20/2020 5:27:44 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/18/2020 9:15:32 AM
Amyris Appoints Sheila Shekar Pollak As Chief Marketing Officer Of Biossance PR Newswire (US) - 8/14/2020 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/12/2020 7:48:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/12/2020 7:47:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/12/2020 7:47:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/12/2020 7:46:54 PM
finesand   Thursday, 08/24/17 05:49:38 AM
Re: finesand post# 3771
Post # of 4115 
The Struggle Continues, AMRS Shall State end of Dilution

I can add the following findings regarding insecurity of investors and the short thesis:

- $4.26 is the next T-1 T-2 AD Warrants threshold.

- TAB R&D Noted of $3.7M to be payed until EOY '17. If done in cash great, if using equity at lowered conversion price down it goes.

- $20.7M 10% pa interest Guanfu Credit left, which could be payed in equity at 90% VWAP of 90d closing price as well. Same thing here, if using equity, down it goes.

Above are two potential triggers for lowering the T-1 T-2 Cash-Warrant conversion prices, which is truly feared. I spoke with one long term short holder at $3.50 and she is using this 'instrument'.

The Vivo deal already brought down the conversion price and triggered AD Warrants with DSM's blessing - might have been even their requirement to average down further.
Now the price tag for them is at $5.30 for conversions.

What poor retail surely needs to know from the company is, whether they will pay down the mentioned debt in cash and end the dilution spiral reducing common's stake in the company.
If that can be assure by the company, the awaited recovery at least around $5.30 matching purchase average should work out.

It is a struggle between trust, opportunity and deception.
Especially deception plays a big role in here, some even thought T-1 would have been offered above $17/sh not doing the dilutive math in detail, bringing it down to $6.30. Now - again - we are at $5.30. Tough decisions and chart seems to capture just that.



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences